Table 1 Baseline characteristics of KMT2Ar adult AML patients.
n = 205 | |
|---|---|
Female sex | 111 (54.1%) |
Median age in years (range) | 48.1 (18.6–86.2) |
Age ≥ 60 years | 51 (24.9%) |
AML type | |
De novo AML | 148 (72.2%) |
Secondary AML | 57 (27.8%) |
AML after MDS | 14 (6.8%) |
Therapy-related AML | 43 (21%) |
Hemoglobin (g/dL) | 9.5 [Q1 = 8.3, Q3 = 11.3] |
WBC (×109/L) | 23.1 [Q1 = 4.7, Q3 = 58] |
(>100 × 109/L) | 21 (10.2%) |
Platelets (×109/L) | 51.5 [Q1 = 29.8, Q3 = 107.5] |
Bone marrow % of blasts | 83 [Q1 = 70.2, Q3 = 90] |
Chromosomal aberrations | |
t(9;11) | 101 (49%) |
t(11;19) | 33 (16%) |
t(6;11) | 24 (12%) |
t(10;11) | 10 (5%) |
t(11;17) | 10 (5%) |
Other KMT2Ar | 27 (13%) |
Additional chromosomal aberrations | 85 (41.6%) |
Complex aberrations (≥2 apart from KMT2Ar) | 38 (19%) |
Trisomy 8 | 37 (18%) |
Derivative 11 | 12 (6%) |
ELN 2022 | |
Favorable | – |
Intermediate | 101 (49.3%) |
Adverse | 104 (50.7%) |
Treatment | |
Intensive | 195 (95%) |
Non-intensive | 10 (5%) |
Composite complete response | 120 (63.8%) |
Early death | |
30-day mortality | 28 (13.6%) |
60-day mortality | 36 (17.6%) |
Allogeneic HSCT | 88 (42.9%) |
In CR1 | 48 (23.4%) |
In CR2 or later | 15 (7.3%) |
Unknown response at allo-HSCT | 25 (12.2%) |
Median survival in years (95% CI) | 1.4 (1.1–1.7) |
